Charles Schwab
MDGL icon

Charles Schwab’s Madrigal Pharmaceuticals MDGL Stock Holding History

Charles Schwab’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$99M Sell
184,324
-32,396
-15% -$16.6M 0.01% 800
2026
Q1 		$113M Sell
216,720
-2,379
-1% -$1.14M 0.02% 659
2025
Q4 		$128M Buy
219,099
+5,447
+3% +$2.78M 0.02% 597
2025
Q3 		$98M Buy
213,652
+60,567
+40% +$22.6M 0.02% 727
2025
Q2 		$46.3M Buy
153,085
+1,834
+1% +$546K 0.01% 1151
2025
Q1 		$50.1M Buy
151,251
+505
+0.3% +$166K 0.01% 1069
2024
Q4 		$46.5M Buy
150,746
+2,776
+2% +$781K 0.01% 1179
2024
Q3 		$31.4M Buy
147,970
+9,656
+7% +$2.47M 0.01% 1434
2024
Q2 		$38.8M Buy
138,314
+15,622
+13% +$3.72M 0.01% 1249
2024
Q1 		$32.8M Buy
122,692
+2,480
+2% +$584K 0.01% 1300
2023
Q4 		$27.8M Buy
120,212
+10,711
+10% +$1.87M 0.01% 1381
2023
Q3 		$16M Buy
109,501
+11,083
+11% +$2.09M ﹤0.01% 1638
2023
Q2 		$22.7M Buy
98,418
+6,796
+7% +$1.84M 0.01% 1407
2023
Q1 		$22.2M Buy
91,622
+172
+0.2% +$46.9K 0.01% 1388
2022
Q4 		$26.5M Buy
91,450
+1,971
+2% +$193K 0.01% 1229
2022
Q3 		$5.82M Buy
89,479
+1,229
+1% +$85.4K ﹤0.01% 2132
2022
Q2 		$6.32M Sell
88,250
-224
-0.3% -$16.5K ﹤0.01% 2085
2022
Q1 		$8.68M Buy
88,474
+1,756
+2% +$148K ﹤0.01% 2030
2021
Q4 		$7.35M Buy
86,718
+3,850
+5% +$316K ﹤0.01% 2155
2021
Q3 		$6.61M Buy
82,868
+10,586
+15% +$914K ﹤0.01% 2242
2021
Q2 		$7.04M Buy
72,282
+7,923
+12% +$938K ﹤0.01% 2186
2021
Q1 		$7.53M Buy
64,359
+4,171
+7% +$486K ﹤0.01% 2093
2020
Q4 		$6.69M Buy
60,188
+873
+1% +$107K ﹤0.01% 2080
2020
Q3 		$7.04M Sell
59,315
-2,307
-4% -$250K ﹤0.01% 1897
2020
Q2 		$6.98M Buy
61,622
+3,382
+6% +$333K ﹤0.01% 1863
2020
Q1 		$3.89M Buy
58,240
+3,431
+6% +$286K ﹤0.01% 1949
2019
Q4 		$4.99M Buy
54,809
+6,477
+13% +$628K ﹤0.01% 2013
2019
Q3 		$4.17M Buy
48,332
+1,015
+2% +$95.2K ﹤0.01% 2059
2019
Q2 		$4.96M Buy
47,317
+2,427
+5% +$260K ﹤0.01% 1974
2019
Q1 		$5.62M Buy
44,890
+2,553
+6% +$317K ﹤0.01% 1928
2018
Q4 		$4.77M Sell
42,337
-601
-1% -$93K ﹤0.01% 1929
2018
Q3 		$9.2M Buy
42,938
+29,618
+222% +$7.43M 0.01% 1697
2018
Q2 		$3.73M Buy
13,320
+3,392
+34% +$596K ﹤0.01% 2145
2018
Q1 		$1.16M Buy
9,928
+1,100
+12% +$136K ﹤0.01% 2479
2017
Q4 		$811K Sell
8,828
-4,972
-36% -$284K ﹤0.01% 2582
2017
Q3 		$621K Hold
13,800
– – ﹤0.01% 2656
2017
Q2 		$225K Buy
+13,800
New +$216K ﹤0.01% 2989
2016
Q3 		– Sell
-1,254
Closed -$12K – 3045
2016
Q2 		$12K Sell
1,254
-5,480
-81% -$65.7K ﹤0.01% 3098
2016
Q1 		$57K Sell
6,734
-5,036
-43% -$42.1K ﹤0.01% 3024
2015
Q4 		$146K Buy
11,770
+2,556
+28% +$70.1K ﹤0.01% 3011
2015
Q3 		$562K Buy
9,214
+746
+9% +$53.8K ﹤0.01% 2578
2015
Q2 		$661K Sell
8,468
-1,008
-11% -$84.6K ﹤0.01% 2571
2015
Q1 		$644K Buy
9,476
+3,926
+71% +$337K ﹤0.01% 2543
2014
Q4 		$515K Buy
5,550
+130
+2% +$13.4K ﹤0.01% 2612
2014
Q3 		$571K Buy
5,420
+105
+2% +$14.6K ﹤0.01% 2538
2014
Q2 		$761K Sell
5,315
-33
-0.6% -$4.82K ﹤0.01% 2452
2014
Q1 		$807K Buy
5,348
+1,491
+39% +$294K ﹤0.01% 2389
2013
Q4 		$708K Buy
3,857
+878
+29% +$161K ﹤0.01% 2438
2013
Q3 		$668K Buy
2,979
+136
+5% +$28.9K ﹤0.01% 2417
2013
Q2 		$498K Buy
+2,843
New +$741K ﹤0.01% 2531

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Charles Schwab's MDGL Position: Q2 2026 in Review

Charles Schwab reduced its Madrigal Pharmaceuticals (MDGL) stake by 15% in Q2 2026, selling an estimated $16.6M and leaving 184,324 shares worth $99M. The position accounts for 0.01% of the portfolio, ranked #800.

Charles Schwab first reported a position in MDGL in Q2 2013 and has held it in 50 quarters since. The position peaked at $128M in Q4 2025. 412 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Charles Schwab held 184,324 shares of Madrigal Pharmaceuticals worth $99M as of Q2 2026.
  • Charles Schwab sold 32,396 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $16.6M.
  • Madrigal Pharmaceuticals made up 0.01% of Charles Schwab's portfolio in Q2 2026, its #800 holding.
  • Charles Schwab first reported a position in Madrigal Pharmaceuticals in Q2 2013 and has held it in 50 quarters since.
  • Charles Schwab's Madrigal Pharmaceuticals position peaked at $128M in Q4 2025.
  • 412 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.